XERS - CIK 0001867096
Xeris Biopharma Holdings, Inc. (XERS) reported net income of $554.00K for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | $554.00K | +101.0% |
| FY 2024 | -$54.84M | +11.9% |
| FY 2023 | -$62.26M | +34.2% |
| FY 2022 | -$94.66M | +22.9% |
| FY 2021 | -$122.72M | -34.7% |
| FY 2020 | -$91.14M | - |
Xeris Biopharma Holdings, Inc. (XERS) reported net income of $554.00K for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2020 and fiscal 2025, Xeris Biopharma Holdings, Inc.'s net income grew from -$91.14M to $554.00K.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.